Free shipping on all orders over $ 500

DS-1001b (Safusidenib t-Butylamine)

Cat. No. M9533
DS-1001b (Safusidenib t-Butylamine) Structure
Synonym:

Safusidenib

Size Price Availability Quantity
5mg USD 150  USD150 In stock
10mg USD 255  USD255 In stock
25mg USD 465  USD465 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

DS-1001b (Safusidenib t-Butylamine) is a potent, orally bioavailable, selective mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor with antitumor activity. DS-1001b (Safusidenib t-Butylamine) impairs the proliferation of IDH1 mutant chondrosarcoma cell lines and decreases 2-HG levels. DS-1001b exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively.

In vivo, Safusidenib (DS-1001b) has antineoplastic activity in JJ012 xenografts. Continuous administration of Safusidenib (mixed with sterilized pellet food and fed continuously for 6 weeks) impairs tumor growth in xenograft mice.

Chemical Information
Molecular Weight 608.92
Formula C29H29Cl3FN3O4
CAS Number 1898207-64-1
Solubility (25°C) DMSO ≥ 18 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yukino Machida, et al. Mol Cancer Ther . A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model

[2] Makoto Nakagawa, et al. Oncogene. Selective Inhibition of Mutant IDH1 by DS-1001b Ameliorates Aberrant Histone Modifications and Impairs Tumor Activity in Chondrosarcoma.

Related Isocitrate Dehydrogenase (IDH) Products
Mutant IDH1-IN-4

Mutant IDH1-IN-4 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH 1) with an IC50 value of ≤ 0.5 μM for mutant IDH 1 in R132H, HT1080 and U87R132H cells.

(S,S)-GSK321

(S,S)-GSK321 is the (S,S)-enantiomer of GSK321.GSK321 is a potent inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme.

IDH1 Inhibitor 1

IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-permeable, selective mutant IDH1 inhibitor that inhibits IDH1R132H, IDH1R132C, and IDH1WT with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM, respectively. possesses antitumor activity.

IDH1 Inhibitor 7

IDH1 Inhibitor 7 is an IDH1 inhibitor with an IC50 of less than 100 nM.

(R,R)-GSK321

(R,R)-GSK321 is an isomer of GSK321 and a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: DS-1001b (Safusidenib t-Butylamine), Safusidenib supplier, Isocitrate Dehydrogenase (IDH), inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.